These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11143762)

  • 61. The role of hypertriglyceridemia in atherosclerosis.
    Le NA; Walter MF
    Curr Atheroscler Rep; 2007 Aug; 9(2):110-5. PubMed ID: 17877919
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study.
    Ndumele CE; Matsushita K; Astor B; Virani SS; Mora S; Williams EK; Hoogeveen RC; Blumenthal RS; Sharrett AR; Ballantyne CM; Coresh J
    Eur J Prev Cardiol; 2014 Jul; 21(7):866-75. PubMed ID: 23109406
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion.
    Avramoglu RK; Qiu W; Adeli K
    Front Biosci; 2003 Jan; 8():d464-76. PubMed ID: 12456312
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
    Brunzell JD; Ayyobi AF
    Am J Med; 2003 Dec; 115 Suppl 8A():24S-28S. PubMed ID: 14678862
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects.
    Gianturco SH; Bradley WA
    Clin Cardiol; 1999 Jun; 22(6 Suppl):II7-14. PubMed ID: 10376191
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Abnormalities in lipoprotein metabolism in hemodialysis patients.
    Königer M; Quaschning T; Wanner C; Schollmeyer P; Krämer-Guth A
    Kidney Int Suppl; 1999 Jul; 71():S248-50. PubMed ID: 10412790
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Postprandial hyperlipidemia as a potential residual risk factor.
    Nakamura K; Miyoshi T; Yunoki K; Ito H
    J Cardiol; 2016 Apr; 67(4):335-9. PubMed ID: 26744235
    [TBL] [Abstract][Full Text] [Related]  

  • 69. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects.
    Ambrosch A; Mühlen I; Kopf D; Augustin W; Dierkes J; König W; Luley C; Lehnert H
    Diabetes Care; 1998 Dec; 21(12):2077-84. PubMed ID: 9839097
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Atherosclerosis and metabolic disease].
    Tsuji M; Ishii J
    Rinsho Byori; 2004 Feb; 52(2):126-35. PubMed ID: 15027316
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical implications of the insulin resistance syndrome.
    Garvey WT; Hermayer KL
    Clin Cornerstone; 1998; 1(3):13-28. PubMed ID: 10682170
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cardiovascular risk continuum: implications of insulin resistance and diabetes.
    Hsueh WA; Law RE
    Am J Med; 1998 Jul; 105(1A):4S-14S. PubMed ID: 9707262
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study.
    Arad Y; Newstein D; Cadet F; Roth M; Guerci AD
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2051-8. PubMed ID: 11742884
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of syndromes of insulin resistance with coronary artery disease.
    LeWinter MM
    Coron Artery Dis; 2005 Dec; 16(8):477-80. PubMed ID: 16319657
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The mixed benefit of low lipoprotein(a) in type 2 diabetes.
    Hermans MP; Ahn SA; Rousseau MF
    Lipids Health Dis; 2017 Sep; 16(1):171. PubMed ID: 28899393
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
    Watts GF; Ooi EM; Chan DC
    Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.